Novo Nordisk sales by therapy area 2021-2022

Published by
Matej Mikulic,
Feb 6, 2023
Danish drug manufacturer Novo Nordisk generated some 156 billion kroner - or some 88 percent of its total sales - in the diabetes and obesity care segment. The biopharma/rare disease segment was significantly lower, generating some 20.5 billion kroner of the company's total sales.

Novo Nordisk's sales by therapeutic area in 2021 and 2022 (in million DKK)

© Statista 2023
Download
Show detailed source information?
Register for free
Already a member?
Log in
Source

Use Ask Statista Research Service

Release date

February 2023

Region

Worldwide

Survey time period

2021 and 2022

Citation formats
Statista Accounts: Access All Statistics. Starting from $588 USD / Year
Basic Account
Get to know the platform

You only have access to basic statistics.
This statistic is not included in your account.

Starter Account
The ideal entry-level account for individual users
  • Instant access to 1m statistics
  • Download in XLS, PDF & PNG format
  • Detailed references
$69 USD $49 USD / Month *
in the first 12 months
Professional Account
Full access

Business Solutions including all features.

* Prices do not include sales tax.

Other statistics that may interest you

The most important statistics
The most important statistics
The most important statistics
The most important statistics
The most important statistics

Other statistics that may interest you

Global positioning

6

Key metrics

4

Segments

4

Competitors

5

Diabetes - a growing market

5

Further related statistics

19

Further Content: You might find this interesting as well

Statistics

Topics

Novo NordiskGlobal pharmaceutical industryPharmaceutical industry in the U.S.DiabetesDiabetes in China
Statista Accounts: Access All Statistics. Starting from $588 USD / Year
Learn more about how Statista can support your business.
Menu